GenSight Biologics is a clinical-stage biotechnology company based in France. Co. is engaged in discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system by combining a gene therapy-based approach with its core technology platforms of mitochondrial targeting sequence, or MTS, and optogenetics. Co.'s initial focus has been on developing therapies for severe retinal diseases, with the goal of preserving or restoring vision in patients suffering from sight-threatening ophthalmic diseases. Co.'s product pipeline comprises two candidates for the treatment of sight-threatening retinal degenerative diseases, GSO1O and GSO3O.

Median Technologies is engaged in medical imaging. Co. develops software applications for the interpretation and management of medical images, whose purpose is to automatically detect and quantitatively measure abnormalities that may be signs of diseases. In addition to being involved in patient care applications, Co.'s software is used today used by biotechnology companies and pharmaceutical companies during their oncology clinical trials. Co.'s activities are structured around three strategic areas: Imaging for patients with cancer; Imaging for oncology clinical trials and Imaging Phenomics.